In Vitro Toxicology Testing Market: Key Players and Future Growth Potential

-

The global in vitro toxicology testing market size is projected to reach USD 18.6 billion by 2027 from USD 11.2 billion in 2022, growing at a CAGR of 10.8%. The primary growth factors such as increasing R&D expenditure to detect toxicity at an early stage during drug development drive the market. Also, the increasing focus of the pharmaceutical and cosmetics industries on using in vitro methods are expected to offer significant opportunities for market growth in the coming years.

Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), General Electric Company (US), Eurofins Scientific (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Evotec (UK), SGS S.A. (Switzerland), QIAGEN (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, and expansions.

Thermo Fisher Scientific was one of the leading players in the in vitro toxicology testing market in 2021. The company is a global manufacturer of laboratory equipments, analytical instruments, consumables, services and reagents for the in vitro toxicology testing market. The company operates from Life Science Business segment in In vitro toxicity testing market. The company has a significant global footprint owing to its strong sales and distribution network.

Merck is a leading science and technology company with a strong global presence in more than 120 countries. The company operates from life science segment in In vitro toxicology market. The company has a wide costumer base which supports company’s portfolio of life science products. The company majorly focuses on geographical expansions to increase its costomer base.

Research Applications

> Drug Discovery Development

In vitro toxicology testing is used in drug discovery and development to assess the safety of potential new drugs and to determine the dose levels that can be safely administered. This testing is conducted in a laboratory setting using cell culture, animal models, and computer models to evaluate the potential toxicity of a compound. In vitro tests can be used to evaluate the biological effects of a drug on cells, organs, and tissues, as well as to examine the potential for drug-drug interactions. These tests can also be used to identify biomarkers of toxicity and to predict the pharmacokinetics and pharmacodynamics of a drug. In vitro toxicology testing can help to reduce the number of animal studies needed to evaluate the safety of a drug, as well as to reduce the costs associated with drug development.

> Toxicity Profiling

In vitro toxicology testing in toxicity profiling can include tests such as Ames tests, mammalian cell culture tests, cytotoxicity testing, cell-based assays, and genotoxicity assays. These tests can be used to determine the potential toxicity of a new drug or chemical compound in order to assess its safety for human use or environmental exposure. Ames tests are used to detect mutagenic potential, mammalian cell culture tests measure cellular responses to potential toxins, cytotoxicity testing evaluates the toxicity of a compound based on the effects on cell viability, and cell-based assays measure changes in cell structure or function in response to a compound. Genotoxicity assays measure the potential for cytogenetic damage of a compound.

> Carcinogenicity

In vitro carcinogenicity testing is conducted in the laboratory using cell cultures to determine if a substance has the potential to cause cancer. This type of testing is used to identify potential carcinogens and evaluate their effects on cells and tissue. Tests typically involve exposing cells to a substance or its derivatives and measuring the changes in cell morphology, cell viability, and gene expression. Some tests may also assess the ability of a substance to induce genetic mutations or other types of chromosomal alterations. The results of these tests can help to identify potential carcinogens and inform the risk assessment process.

> Genotoxicit

Genotoxicity is the ability of a substance to damage genetic material, and can be caused by physical, chemical or biological agents. In vitro toxicology testing is used to evaluate the potential genotoxicity of a substance. In vitro genotoxicity tests typically involve exposing cultured cells to varying concentrations of a test substance and then analyzing the cells for signs of genetic damage. Tests used to assess genotoxicity include the Ames test, the micronucleus test, and the comet assay. The results of these tests can provide valuable information about the potential genotoxicity of a substance, which is important for assessing its safety for use in humans.

Geographically, the market is divided into North America, Europe, Asia-Pacific, South America, and the Middle East Africa. The APAC market is projected to register the highest growth during the forecast period. Factors such as, opposition to animal testing resulting in the use of alternate methods.

Related Links:

https://www.marketsandmarkets.com/Market-Reports/in-vitro-toxicology-testing-market-209577065.html

https://www.marketsandmarkets.com/ResearchInsight/in-vitro-toxicology-testing-market.asp

https://www.prnewswire.co.uk/news-releases/in-vitro-toxicology-testing-market-worth-18-6-billion-by-2027-exclusive-report-by-marketsandmarkets-tm--867340077.html

https://www.globenewswire.com/news-release/2022/11/11/2554094/0/en/In-Vitro-Toxicology-Testing-Market-to-Hit-18-6-billion-by-2027-Exclusive-Report-by-MarketsandMarkets.html

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more